
Tensive raises €500,000 from Invitalia and Unicredit
Italy-based biomedical startup Tensive has raised a €500,000 funding round from state-backed venture capital firm Invitalia Ventures and Unicredit.
Invitalia, through its Italia Venture I fund, and Unicredit participated in the round, each providing a €250,000 equity ticket to support the transaction, according to press reports.
The round raised the company's total amount of funding to €1.9m. The company claims the funding will be used to further develop its product, which is in pre-clinical development phase and is yet to be tested in human patients.
Italia Venture I fund, which has recently secured a €5m capital commitment from Fondazione di Sardegna and reached a total capital commitment of €65m, expects to reach its €100m target in September 2017. The vehicle counts Italy's Cassa Depositi e Presiti, Cisco and Metec among its investors.
Company
Based in Milan, Tensive is a biomedical business founded in 2012 following a spin-off from Filarete Fundation. The company develops biodegradable prostheses, which offer natural blood vessels and adipose tissue reconstruction. The company's flagship product, Regenera, is used in breast reconstruction.
People
Invitalia Ventures – Salvo Mizzi (CEO).
Tensive – Alberto Cantaluppi (chair); Gianfranco Bellezza (CEO).
Advisers
Equity (Unicredit) – Legance Studio Legale Associato (legal).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater